Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the…